Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

By I. Guha, J. Parkes, P. Roderick, D. Chattopadhyay, R. Cross, S. Harris, P. Kaye, A. Burt, S. Ryder, G. Aithal and 2 more. Hepatology, 2007

760 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/c93ae9ce99b8e09f1d9a900e15a40bd0bf07d2f3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Z. Younossi
2. A. Sanyal
3. K. Cusi
4. E. Brunt
5. J. Lavine
6. A. Diehl
7. N. Chalasani
8. Vincent Wai-Sun Wong

In Hepatology

1. Z. Younossi
2. K. Cusi
3. A. Sanyal
4. E. Brunt
5. A. Diehl
6. C. Day
7. M. H. Murad
8. X. Forns

Citations in the corpus

• EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. (2016, neutral): “84 43 96 82 80 - Predicts liver-related events [37, 38], incident diabetes [39], all-cause and CV mortality [40] - Changes in NFS predict mortality [38] Guha, 2008 [41] ELF – Enhanced Liver Fibrosis HA, TIMP1, PIIINP 192 >0.”
• Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. (2013, methodology): “The ELF test combines, in an algorithm, measurements from assays for hyaluronic acid, procollagen III amino terminal peptide, and tissue inhibitor of metalloproteinase 1 to generate an ELF score that correlates strongly to the extent of liver fibrosis and/or cirrhosis.(39) Caspase-cleaved keratin-18”
• Noninvasive assessment of liver fibrosis (2011, methodology): “Recently, the utility of the Enhanced Liver Fibrosis panel (ELF) has been validated in an independent cohort of 196 patients with NAFLD.47 The ELF panel had an accuracy of 0.90 (measured as AUROC) in identifying individuals with severe fibrosis, 0.82 for those with moderate fibrosis, and 0.76 for th”
• Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years (2010, result): “Additionally, a significant proportion of patients are in the gray zone, and their fibrosis stage is undetermined. As such, this study showed that the commonly used scores had limited sensitivity in detecting changes in fibrosis stage with time. On the other hand, direct biomarkers of fibrosis and f”
• The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012, result): “, measured CK18 fragments in plasma that had been obtained from 44 consecutive patients with suspected NAFLD at the time of liver biopsy, and correlated the findings with hepatic immunohistochemistry data.(72) Plasma CK18 fragments were markedly increased in patients with NASH compared with patients”
• Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases (2019, background): “It is a joint effort of the Liver Disease Research Branch of the National Institute of Diabetes and Digestive and Kidney Diseases and the Division of Specialized Information Services of the National Library of Medicine, National Institutes of Health. gUIDaNCe StateMeNtS • Drug-induced AIH-like liver”
• Non-alcoholic fatty liver disease: the mist gradually clears. (2008, methodology): “This score has recently been combined with the European Liver Fibrosis (ELF) panel of serum fibrosis markers [53] and shown to have an accuracy of over 90% in differentiating different fibrosis stages in NAFLD [54].”